NO784192L - Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika - Google Patents

Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika

Info

Publication number: NO784192L
Authority: NO; Norway
Prior art keywords: chloroethyl; oxo; oxazaphosphorinane; acid; salt
Prior art date: 1977-12-14

Application number

NO784192A

Other languages

English (en)

Norwegian (no)

Inventor

Norbert Brock

Original Assignee

Asta Werke Ag Chem Fab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-14

Filing date

1978-12-13

Publication date

1979-06-15

1977-12-14 Priority claimed from DE2756018A external-priority patent/DE2756018C2/de

1978-12-13 Application filed by Asta Werke Ag Chem Fab filed Critical Asta Werke Ag Chem Fab

1979-06-15 Publication of NO784192L publication Critical patent/NO784192L/no

Links

238000002360 preparation method Methods 0.000 title claims description 10
238000000034 method Methods 0.000 title claims description 8
230000001085 cytostatic effect Effects 0.000 title description 26
239000000824 cytostatic agent Substances 0.000 title description 24
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims description 15
229960001101 ifosfamide Drugs 0.000 claims description 15
229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 14
159000000000 sodium salts Chemical class 0.000 claims description 11
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 9
229960004397 cyclophosphamide Drugs 0.000 claims description 7
229960000875 trofosfamide Drugs 0.000 claims description 7
ZSZKJARKHWCBJK-UHFFFAOYSA-N 2-[[3-(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-yl]amino]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCNP1(=O)OCCCN1CCCl ZSZKJARKHWCBJK-UHFFFAOYSA-N 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
229950008275 sufosfamide Drugs 0.000 claims description 4
150000001447 alkali salts Chemical class 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims 2
MRIMWDXKBILRPB-UHFFFAOYSA-N O=P1NCCCO1 Chemical compound O=P1NCCCO1 MRIMWDXKBILRPB-UHFFFAOYSA-N 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000000694 effects Effects 0.000 description 24
150000001875 compounds Chemical class 0.000 description 13
210000003932 urinary bladder Anatomy 0.000 description 11
206010028980 Neoplasm Diseases 0.000 description 9
125000003396 thiol group Chemical group [H]S* 0.000 description 7
201000011510 cancer Diseases 0.000 description 6
150000007513 acids Chemical class 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
210000001635 urinary tract Anatomy 0.000 description 5
210000003734 kidney Anatomy 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
230000006378 damage Effects 0.000 description 3
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001784 detoxification Methods 0.000 description 2
235000014103 egg white Nutrition 0.000 description 2
210000000969 egg white Anatomy 0.000 description 2
COSZWAUYIUYQBS-UHFFFAOYSA-B hexapotassium hexasodium 3-carboxy-3-hydroxypentanedioate 2-hydroxypropane-1,2,3-tricarboxylate hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[K+].[K+].[K+].[K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O COSZWAUYIUYQBS-UHFFFAOYSA-B 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000007794 irritation Effects 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
OKVLRTXOHOBONS-UHFFFAOYSA-N 2-methyl-3-sulfanylpropane-1-sulfonic acid Chemical compound SCC(C)CS(O)(=O)=O OKVLRTXOHOBONS-UHFFFAOYSA-N 0.000 description 1
ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
OBDVFOBWBHMJDG-UHFFFAOYSA-N 3-mercapto-1-propanesulfonic acid Chemical compound OS(=O)(=O)CCCS OBDVFOBWBHMJDG-UHFFFAOYSA-N 0.000 description 1
HMEJBVOVTCTWRG-UHFFFAOYSA-N 6-sulfanylhexane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCCCS HMEJBVOVTCTWRG-UHFFFAOYSA-N 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
JYCULSYEFRCGNR-UHFFFAOYSA-N O=P1OC=CC=N1 Chemical class O=P1OC=CC=N1 JYCULSYEFRCGNR-UHFFFAOYSA-N 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000005584 early death Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
ZQRHGLVWSWEITI-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinin-2-amine Chemical compound ClCCN(CCCl)P1(=O)OC=CC=N1 ZQRHGLVWSWEITI-UHFFFAOYSA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000009120 supportive therapy Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
229960004560 triaziquone Drugs 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

NO784192A 1977-12-14 1978-12-13 Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika NO784192L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE2756018A DE2756018C2 (de)	1977-12-14	1977-12-14	Verwendung von Salzen von Mercaptoalkansulfonsäuren
DE2827625		1978-06-23

Publications (1)

Publication Number	Publication Date
NO784192L true NO784192L (no)	1979-06-15

Family

ID=25773277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO784192A NO784192L (no)	1977-12-14	1978-12-13	Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika

Country Status (6)

Country	Link
US (1)	US4220660A (da)
EP (1)	EP0002495B1 (da)
JP (1)	JPS54101432A (da)
DK (1)	DK154608C (da)
FI (1)	FI783756A (da)
NO (1)	NO784192L (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA851062B (en) *	1984-03-01	1985-11-27	Asta Werke Ag Chem Fab	Salts of oxazaphosphorine derivatives and process for their production
US5244920A (en) *	1985-04-15	1993-09-14	Schering Spa	Pharmaceutical compositions having therapeutical activity based on mercaptoethansulphonic arginine salt
IT1185551B (it) *	1985-04-15	1987-11-12	Schering Spa	Composizioni farmaceutiche a base di acido mercaptoetansolfonico ad attivita' terapeutica,derivati salini organici dell'acido mercaptoetansolfonico utili per tali composizioni e relativo procedimento di preparazione
ES2040394T3 (es) *	1988-03-19	1993-10-16	Asta Medica Aktiengesellschaft	Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
JPH01174407U (da) *	1988-05-26	1989-12-12
DE4342091A1 (de) *	1993-12-09	1995-06-14	Asta Medica Ag	Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US6197831B1 (en) *	1999-02-09	2001-03-06	Bionumerik Pharmaceuticals, Inc.	Method of treating septic shock
US6077838A (en) *	1999-06-08	2000-06-20	Bionumerik Pharmaceuticals, Inc.	Method of treating hangover
WO2001049822A2 (fr) *	1999-12-29	2001-07-12	Sergei Mikhailovich Zenovich	Agents physiologiquement actifs contenant dithioglyols et leur application dans differentes secteurs
US6245815B1 (en) *	2000-04-15	2001-06-12	Bionumerik Pharmaceuticals, Inc.	Method of treating alcoholism and complications resulting therefrom
US6291441B1 (en) *	2000-09-27	2001-09-18	Frederick H. Hausheer	Method of treating inflammatory bowel disorders
US6352979B1 (en) *	2001-08-20	2002-03-05	Lucinda Lizcano	Method of treating snakebite and complications resulting therefrom
AU2003276689B2 (en) *	2002-09-05	2009-04-09	Bharat Serums And Vaccines Ltd.	Liquid stable composition of oxazaphosphorine with mesna
US7025998B2 (en)	2003-05-30	2006-04-11	Rotta Research Laboratorium S.P.A.	Phytoestrogens and probiotic for women's health
WO2005032515A1 (en) *	2003-10-01	2005-04-14	Baxter International Inc.	New use, pharmaceutical preparations as well as a process for their production
AU2004299131B2 (en) *	2003-12-17	2010-05-13	Bionumerik Pharmaceuticals, Inc.	Process for synthesizing disulfides
US20060063742A1 (en) *	2004-09-21	2006-03-23	Hausheer Frederick H	Method of treatment for or protection against lymphedema

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1119721A (en) *	1965-05-07	1968-07-10	Ucb Sa	Mucolytic mercapto-sulphonates

1978
- 1978-12-06 EP EP78101583A patent/EP0002495B1/de not_active Expired
- 1978-12-06 US US05/967,000 patent/US4220660A/en not_active Expired - Lifetime
- 1978-12-07 FI FI783756A patent/FI783756A/fi unknown
- 1978-12-07 DK DK553978A patent/DK154608C/da not_active IP Right Cessation
- 1978-12-13 JP JP15906678A patent/JPS54101432A/ja active Granted
- 1978-12-13 NO NO784192A patent/NO784192L/no unknown

Also Published As

Publication number	Publication date
JPS54101432A (en)	1979-08-10
DK154608B (da)	1988-12-05
DK553978A (da)	1979-06-15
FI783756A (fi)	1979-06-15
EP0002495A1 (de)	1979-06-27
JPS6154006B2 (da)	1986-11-20
DK154608C (da)	1989-05-08
EP0002495B1 (de)	1984-02-15
US4220660A (en)	1980-09-02

Publication	Publication Date	Title
NO784192L (no)	1979-06-15	Fremgangsmaate til fremstilling av avgiftede preparater av cytostatika
US20030232793A1 (en)	2003-12-18	Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
George et al.	1974	Metabolism of isoprenaline in the intestine
PT1339411E (pt)	2007-10-12	''utilização de ácido zoledrónico para tratamento da dor''
BR0010257A (pt)	2002-02-13	Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, método para tratamento ou profilaxia de condições associadas com a inibição da carboxipeptidase u, kits de partes, e, método de tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da carboxipeptidase u e um mecanismo antitrombótico diferente são necessários ou desejados
CN108366975A (zh)	2018-08-03	使用脱氧胆酸和其盐对堆积的脂肪的治疗
Lavigne et al.	1974	The treatment of experimental peritonitis with intraperitoneal betadine solution
CA2104868C (en)	2003-02-25	Method and products for treating the eye
US5385726A (en)	1995-01-31	Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
US4218471A (en)	1980-08-19	Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents
EP0542807A1 (en)	1993-05-26	Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one
Key et al.	1941	THE LOCAL USE OF SULFANILAMIDE, SULFAPYMDINE AND SULFAMETHYLTHIAZOL
CA2580759C (en)	2013-06-04	Method and composition for treating patients undergoing kidney dialysis
EA022880B1 (ru)	2016-03-31	Способы лечения с применением длительной непрерывной инфузии белиностата
CA1117015A (en)	1982-01-26	Process for producing detoxified pharmaceutical products containing a cytostatically active alkylating agent
EP0783884B1 (en)	2002-09-04	Conagenin as preventive and remedy for diarrhea
JP2004523518A (ja)	2004-08-05	より効能が大きく副作用の少ない癌治療方法
RU2703735C1 (ru)	2019-10-22	Фармацевтическая композиция, содержащая DHMEQ или его аналоги
US6197831B1 (en)	2001-03-06	Method of treating septic shock
US20040086536A1 (en)	2004-05-06	Therapeutic agents and treatment kits for hypertrophic pyloric stenosis
US20060063742A1 (en)	2006-03-23	Method of treatment for or protection against lymphedema
SU1657190A1 (ru)	1991-06-23	Способ профилактики аутоиммунного орхита после оперативного лечени крипторхизма
JPH1179991A (ja)	1999-03-23	移植皮膚又は移植組織の壊死防止剤
US20010041744A1 (en)	2001-11-15	Angiogenesis inhibitors
RU2022100706A (ru)	2023-07-14	Способ лечения инсульта с применением трициклического производного